Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973143 | 0.84 | ERN1 (0.52) | ERN1CYP2A6MAOBMAOAPTPN1 | |
| SCHEMBL30355307 | 0.78 | RAD51 (0.43) | CYP2A6ALDH1A1 | |
| SCHEMBL6901018 | 0.78 | RAD51 (0.43) | CYP2A6ALDH1A1 | |
| SCHEMBL20590003 | 0.78 | ALDH1A1 (0.39) | CYP2A6ALDH1A1 | |
| SCHEMBL24416800 | 0.76 | KDM4E (0.47) | MAOAALDH1A1MCL1LMNA | |
| SCHEMBL1605954 | 0.76 | HTR2A (0.41) | ERN1MAOBMAOAPTPN1ALDH1A1 | |
| SCHEMBL29955194 | 0.76 | TDP1 (0.55) | ERN1CYP2A6MAOBMAOAPTPN1 | |
| SCHEMBL11358448 | 0.76 | TDP1 (0.55) | ERN1CYP2A6MAOBMAOAPTPN1 | |
| SCHEMBL583644 | 0.76 | ALDH1A1 (0.42) | ERN1CYP2A6MAOBMAOAALDH1A1 | |
| SCHEMBL29955930 | 0.76 | ESR2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019142208-A1 | AMBIENT TEMPERATURE CURABLE NON-ISOCYANATE POLYHYDROXYALKYLURETHANE MOIETIES WITH ALDEHYDE CROSS LINKER | Asian Paints Ltd. (IN) | 2019-07-25 | — | — | WO | claimed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-9090562-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8765732-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2697199-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| US-8410088-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142504-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | ERN1 3690/4885CYP2A6 154/4885MAOB 3491/4885 |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | ERN1 3853/4885CYP2A6 3830/4885MAOB 1606/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | ERN1 3853/4885CYP2A6 3830/4885MAOB 1606/4885 |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | ERN1 4868/4885CYP2A6 19/4885MAOB 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.